Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Antisense Therapeutics Limited
  6. News
  7. Summary
    ANP   AU000000ANP4

ANTISENSE THERAPEUTICS LIMITED

(ANP)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

09/23/2021 | 07:29pm EDT

Antisense Therapeutics Limited announced that the ATL1102 Phase II non-ambulant DMD patient plasma protein data was presented on September 24, 2021 at the 26th International Annual Congress of the World Muscle Society in the late breaking news poster titled "ATL1102 treatment in non-ambulant boys with DMD modulates Latent TGF-beta-binding protein 4, and thrombospondin-1, two disease genetic modifiers of ambulant DMD, and CXCL16". ATL1102 was assessed in an open label Phase II study in adolescent non-ambulant patients with DMD demonstrating highly promising trial results. Planned as part of the Phase II study, a large-scale protein analysis (known as a proteomics analysis) of retained blood plasma samples from the non-ambulant DMD patients treated with ATL1102 was undertaken to identify the proteins affected so as to provide further insight into the mode of action and biological activity of ATL1102. At the end of the 24 week dosing period, ATL1102 treated patients demonstrated a statistically significant mean reduction in Thrombospondin-1 (-49%), and increases in LTBP4 (20.7%), soluble CXCL16 (29.9%), and VCAM-1 (18.0%) compared to baseline levels (FDR p-value


ę S&P Capital IQ 2021
All news about ANTISENSE THERAPEUTICS LIMITED
10/03Antisense Therapeutics Appoints Gil Price as New Non-Executive Director
CI
09/24ANTISENSE THERAPEUTICS' : ATL1102 Drug Shows Clinical Potential in Phase 2 Study; Shares J..
MT
09/23Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Po..
CI
09/02PRESS RELEASE : Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec ..
DJ
08/25Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt
CI
08/11ANP Updates on US Regulatory Plans for ATL1102 in DMD
CI
07/27ANTISENSE THERAPEUTICS : Appoints Non-Executive Director as New Chair; Shares Rise 5%
MT
07/27Antisense Therapeutics Limited Announces Executive Changes
CI
07/01ANTISENSE THERAPEUTICS : Morgans rates ANP as Add
AQ
06/27Antisense Therapeutics and Murdoch Children's Research Institute Enter into New R&D Col..
CI
More news
Financials
Sales 2022 1,40 M 1,05 M 1,05 M
Net income 2022 -18,0 M -13,5 M -13,5 M
Net cash 2022 28,4 M 21,3 M 21,3 M
P/E ratio 2022 -10,9x
Yield 2022 -
Capitalization 169 M 127 M 127 M
EV / Sales 2022 101x
EV / Sales 2023 25,3x
Nbr of Employees 8
Free-Float 80,2%
Chart ANTISENSE THERAPEUTICS LIMITED
Duration : Period :
Antisense Therapeutics Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANTISENSE THERAPEUTICS LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,30 AUD
Average target price 0,54 AUD
Spread / Average Target 83,1%
EPS Revisions
Managers and Directors
Mark Diamond Chief Executive Officer, MD & Executive Director
Phillip Allen Hains Chief Financial Officer & Co-Secretary
Robert William Moses Independent Non-Executive Chairman
Nuket Desem Director-Clinical & Regulatory Affairs
Graham F. Mitchell Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
ANTISENSE THERAPEUTICS LIMITED126.92%127
GILEAD SCIENCES, INC.14.61%83 717
BIONTECH SE241.97%67 329
WUXI APPTEC CO., LTD.20.76%62 553
REGENERON PHARMACEUTICALS22.04%61 299
VERTEX PHARMACEUTICALS-23.44%46 941